Suppr超能文献

葡萄糖醛酸化作用将1-(3,4-二甲氧基苯基)-3-(3-乙基戊酰基)-4-羟基-6,7,8-三甲氧基-2-萘甲酸甲酯(S-8921)转化为一种强效的顶端钠依赖性胆汁酸转运蛋白抑制剂,从而产生降胆固醇作用。

Glucuronidation converting methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) to a potent apical sodium-dependent bile acid transporter inhibitor, resulting in a hypocholesterolemic action.

作者信息

Sakamoto Shingo, Kusuhara Hiroyuki, Miyata Kenji, Shimaoka Hiroyuki, Kanazu Takushi, Matsuo Yumiko, Nomura Kohji, Okamura Noboru, Hara Seijiro, Horie Kazutoshi, Baba Takahiko, Sugiyama Yuichi

机构信息

Developmental Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.

出版信息

J Pharmacol Exp Ther. 2007 Aug;322(2):610-8. doi: 10.1124/jpet.106.116426. Epub 2007 Apr 30.

Abstract

Methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) is a novel inhibitor of the ileal apical sodium-dependent bile acid transporter (ASBT/SLC10A2) developed for the treatment of hypercholesterolemia. The present study investigated the hypocholesterolemic action of S-8921 glucuronide (S-8921G) in rats. The plasma concentration of S-8921G was higher than that of S-8921 after single oral administration of S-8921 in normal rats, and S-8921G was excreted into the bile (13% dose). Oral administration of either S-8921 or S-8921G reduced the serum total cholesterol, particularly nonhigh-density lipoprotein cholesterol, in hypercholesterolemic normal rats. In Gunn rats devoid of UDP glucuronosyltransferase-1A activity, S-8921G was undetectable both in the plasma and bile specimens, and only S-8921G administration significantly reduced the serum nonhigh-density lipoprotein cholesterol. An in vitro inhibition study showed that glucuronidation converts S-8921 to a 6000-fold more potent inhibitor of human ASBT (K(i) = 18 nM versus 109 microM). S-8921G was detected both in the portal plasma and loop when S-8921 was administered into the loop of the rat jejunum, although the cumulative amount of S-8921G recovered in the bile was 5-fold greater than that in the loop. The uptake of S-8921G by freshly prepared rat hepatocytes was saturable, and sodium-dependent and -independent systems were involved. Organic anions, such as bromosulfophthalein, estrone 3-sulfate, and taurocholic acid, inhibited the uptake. These results suggest that UDP glucuronosyltransferase-1 isoforms play a critical role in the hypocholesterolemic action of S-8921 by converting S-8921 to a more potent ASBT inhibitor, and organic anion transporter(s) are also involved in its pharmacological action through the biliary excretion of S-8921G.

摘要

1-(3,4-二甲氧基苯基)-3-(3-乙基戊酰基)-4-羟基-6,7,8-三甲氧基-2-萘甲酸甲酯(S-8921)是一种新型的回肠顶端钠依赖性胆汁酸转运体(ASBT/SLC10A2)抑制剂,用于治疗高胆固醇血症。本研究调查了S-8921葡萄糖醛酸苷(S-8921G)在大鼠体内的降胆固醇作用。在正常大鼠单次口服S-8921后,S-8921G的血浆浓度高于S-8921,且S-8921G经胆汁排泄(剂量的13%)。口服S-8921或S-8921G均可降低高胆固醇血症正常大鼠的血清总胆固醇,尤其是非高密度脂蛋白胆固醇。在缺乏UDP葡萄糖醛酸基转移酶-1A活性的Gunn大鼠中,血浆和胆汁标本中均未检测到S-8921G,只有给予S-8921G能显著降低血清非高密度脂蛋白胆固醇。一项体外抑制研究表明,葡萄糖醛酸化使S-8921转化为对人ASBT抑制作用强6000倍的抑制剂(Ki = 18 nM对109 μM)。当将S-8921注入大鼠空肠肠袢时,在门静脉血浆和肠袢中均检测到S-8921G,尽管胆汁中回收的S-8921G累积量比肠袢中的大5倍。新鲜制备的大鼠肝细胞对S-8921G的摄取具有饱和性,涉及钠依赖性和非依赖性系统。有机阴离子,如溴磺酞、雌酮3-硫酸盐和牛磺胆酸,可抑制摄取。这些结果表明,UDP葡萄糖醛酸基转移酶-1同工型通过将S-8921转化为更强效的ASBT抑制剂,在S-8921的降胆固醇作用中起关键作用,有机阴离子转运体也通过S-8921G的胆汁排泄参与其药理作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验